Paclitaxel
Paclitaxel is a cytotoxic chemotherapy drug — a diterpene natural product originally isolated from the bark of the Pacific yew tree (Taxus brevifolia) and now one of the most widely administered anticancer agents in oncology.
Paclitaxel is a cytotoxic chemotherapy drug — a diterpene natural product originally isolated from the bark of the Pacific yew tree (Taxus brevifolia) and now one of the most widely administered anticancer agents in oncology. It belongs to the taxane class, alongside docetaxel, and acts by binding the β-tubulin (TUBB) subunit of assembled microtubules. Rather than depolymerizing microtubules as vinca alkaloids do, paclitaxel hyperstabilizes tubulin polymers, disrupting the dynamic instability the mitotic spindle requires for chromosome segregation; cells arrest at the G2/M transition and undergo apoptosis. Because the effect falls hardest on rapidly dividing cells, paclitaxel has broad-spectrum activity across breast, ovarian, lung, pancreatic, and other malignancies, and it is a standard component of combination regimens — with carboplatin, gemcitabine, doxorubicin, or the HER2-directed antibodies trastuzumab and pertuzumab, among others. Its characteristic toxicities, notably peripheral neuropathy and myelosuppression, constrain dosing.
Paclitaxel is highly lipophilic and poorly water-soluble, and conventional formulations rely on the surfactant Cremophor EL as a vehicle, which contributes hypersensitivity reactions and nonlinear pharmacokinetics of its own. This has driven sustained work on alternative delivery: albumin-bound nanoparticle paclitaxel (Nab-Paclitaxel), oral lipid-based preparations that avoid Cremophor EL entirely, and polymeric, glycopolymer, and chitosan-based nanocarriers designed for pH-responsive or tumor-targeted release, sometimes co-loading a photosensitizer for combined chemo- and photochemotherapy. Delivery format is not merely pharmacokinetic: formulation appears to shape the tumor microenvironment and immune response differently, which is relevant as paclitaxel is increasingly paired with immune checkpoint inhibitors such as pembrolizumab, atezolizumab, and durvalumab, and with the anti-angiogenic antibody bevacizumab. Resistance to paclitaxel remains a central clinical problem and has been linked to signaling through the Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) and MAPK pathways, CD44/JAK2/STAT3 signaling, altered microtubule-associated proteins such as tau (MAPT), and adaptive changes in oxidative stress and mitochondrial metabolism.
Where the papers sit
41 papers from the last 6 months study paclitaxel directly · updated from PubMed 16 Nov 2026
Study type 4 clinical trials · 3 observational · 5 human data · 26 preclinical · 3 unclassified
Themes 5 themes · 1 new direction
-
Stimuli-Responsive Drug Delivery
Nanocarriers are being engineered to improve paclitaxel solubility, uptake, tumor selectivity, and release control. Acidic, reductive, hypoxic, light, and photothermal triggers enable spatial or temporal drug liberation, often with imaging or a second agent. Folate targeting, elacridar co-delivery, and mitochondria-directed designs aim to overcome resistance and intracellular barriers. The work remains predominantly preclinical, emphasizing formulation performance and in vitro antitumor activity rather than clinical outcomes.
10 papers · 24.4%
-
Triple-Negative Breast Cancer
Paclitaxel treatment is moving toward chemoimmunotherapy and combinations that reshape the tumor microenvironment. Durvalumab with paclitaxel, with or without capivasertib or oleclumab, is evaluated alongside immune-response dynamics. Other approaches target PI3K/AKT/mTOR signaling, gut microbiota, cancer-associated fibroblasts, or local drug delivery. The evidence remains a mix of clinical trials and preclinical systems, with response biomarkers and durable benefit still unresolved.
8 papers · 19.5%
-
Platinum Combination Chemotherapy
Paclitaxel is repeatedly combined with carboplatin or cisplatin across lung, ovarian, cervical, endometrial, and nasopharyngeal cancers. Treatment development emphasizes neoadjuvant, inhaled, and targeted delivery strategies alongside established platinum regimens. Resistance recurs through CYP1B1 activity, polyamine metabolism involving SMS1 and SMS2, and broader mitochondrial-immune features of chemotherapy response. The field is moving toward resistance-guided combinations, but evidence spans early delivery studies, laboratory models, and clinical treatment planning.
8 papers · 19.5%
-
HER2-Directed Cancer Therapy
HER2-directed regimens pair taxanes or eribulin with trastuzumab and pertuzumab in advanced cancers. Durable responses in HER2-positive salivary duct carcinoma support extending this strategy beyond breast cancer. Molecular profiling remains central, while a HER2-negative conversion case highlights changing treatment selection. DHP107 food-effect data address paclitaxel formulation pharmacokinetics rather than antitumor efficacy, leaving the cluster clinically focused but somewhat heterogeneous.
4 papers · 9.8%
-
Others — Combination Cancer Therapy
Drug combinations, targeted carriers, ultrasound, and immune stimulation recur across these experimental treatments. Andrographolide, doxorubicin, resiquimod, and photothermal or sonodynamic approaches are used to increase efficacy or reduce toxicity. Resistance mechanisms involving IGF2BP3, m6A-modified CENPA, and reactive oxygen species remain secondary themes. The applications range from solid tumors to lymphoma, keloids, and drug biosynthesis, so no single therapeutic direction dominates.
11 papers · 26.8%
Paclitaxel is studied as a spatially compartmentalized biosynthetic product in Taxus yunnanensis
The Taxus yunnanensis stem model gives paclitaxel a role outside the set’s therapeutic, delivery, resistance, and clinical-treatment categories: spatial metabolomics and transcriptomic analyses identify paclitaxel-pathway intermediates forming distinct metabolic hotspots enriched for early scaffold-forming or late side-chain compounds. This shifts the focus from administering or improving paclitaxel to understanding where its biosynthesis is organized within the producing plant, with implications for addressing limited drug supply 42947487Oct.
Papers
The 41 papers from the last 6 months that study paclitaxel directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Stimuli-Responsive Drug Delivery (10)
- Morphology-Tunable Nanoparticles of Aspartic Acid Paclitaxel Conjugates for Breast Cancer Treatment. ACS nano · 10 Nov 2026 PMID 43007796
- Anisotropic microgels for spatiotemporal co-delivery of anticancer drugs. Journal of materials chemistry. B · 12 Oct 2026 PMID 42862621
- Multifunctional nanoparticles for co-delivery of elacridar and paclitaxel for breast cancer local treatment. International journal of pharmaceutics · 31 Aug 2026 PMID 42674320
- Reductive microenvironment-activated paclitaxel-BODIPY nanoassemblies for self-reporting drug delivery. Organic & biomolecular chemistry · 18 Aug 2026 PMID 42610199
- Theranostic silica nanoparticles for selective and simultaneous delivery of paclitaxel and coumarin to hypoxic tumors. International journal of pharmaceutics · 16 Aug 2026 PMID 42604719
- Light-driven reconfiguration of catanionic self-assembly enables bidirectional modulation of drug-release kinetics. Journal of materials chemistry. B · 11 Aug 2026 PMID 42578394
- Self-assembled paclitaxel-loaded spermidine-geranic acid ionic liquid nanoaggregates: preparation, enhanced cellular uptake, and antitumor efficacy. International journal of pharmaceutics · 1 Aug 2026 PMID 42542261
- Photothermal and photo-oxidation mediated release of lipophilic paclitaxel from liposomes: from formulation to in vitro efficacy and molecular dynamics simulations. International journal of pharmaceutics · 14 Jul 2026 PMID 42447941
- Preparation of bovine serum albumin-γ-cyclodextrin conjugate and its solubilization and delivery performance for paclitaxel. Carbohydrate polymers · 12 Jun 2026 PMID 42285666
- Hierarchical polymer-drug nanoplatform with polydopamine shell and folate targeting for synergistic cancer therapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235199
Triple-Negative Breast Cancer (8)
- Development and clinical validation of HPLC method for precise quantification of paclitaxel in plasma from breast cancer patients. PloS one · 8 Oct 2026 PMID 42848832
- 10-gingerol potentiates paclitaxel efficacy in triple-negative breast cancer by remodeling gut microbiota and suppressing PI3K/AKT/mTOR signaling pathway. Toxicology and applied pharmacology · 7 Oct 2026 PMID 42843603
- Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer. ImmunoHorizons · 22 Sept 2026 PMID 42772938
- Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS. Human cell · 24 Aug 2026 PMID 42635882
- A mitochondria targeting aggregation-induced emission phototheranostic agent for photodynamic synergistic therapy of triple-negative breast cancer. Journal of materials chemistry. B · 19 Aug 2026 PMID 42615305
- Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment. Biomedical microdevices · 11 Aug 2026 PMID 42579029
- Tumor microenvironment improved by nanostructured lipid carriers co-delivering paclitaxel and ubenimex to treat breast cancer. Drug development and industrial pharmacy · 27 Jul 2026 PMID 42505014
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189888
Platinum Combination Chemotherapy (8)
- Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. NEJM evidence · 25 Aug 2026 PMID 42640170
- FA receptor-targeted pH-sensitive polymeric micelles co-encapsulating quercetin and paclitaxel for synergistic reversal of drug resistance in non-small cell lung cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology · 17 Aug 2026 PMID 42607382
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia. Journal of medical economics · 31 Jul 2026 PMID 42535775
- Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Cesarean Radical Hysterectomy in Pregnant Patients With Cervical Cancer: Obstetric, Neonatal, and Surgical Outcomes. The journal of obstetrics and gynaecology research · 23 Jul 2026 PMID 42489393
- Nanoagglomerate-enabled inhaled paclitaxel nanoparticle delivery for lung cancer chemotherapy: Proof-of-concept biodistribution and efficacy studies in biorelevant in vitro and in vivo models. International journal of pharmaceutics · 20 Jul 2026 PMID 42476273
- Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 20 Jul 2026 PMID 42474029
- Discovery of highly selective and potent CYP1B1 inhibitors for overcoming paclitaxel resistance in A549/Taxol cells. European journal of medicinal chemistry · 4 Jul 2026 PMID 42401084
HER2-Directed Cancer Therapy (4)
- HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy. BMJ case reports · 24 Aug 2026 PMID 42637511
- Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report. Journal of gastrointestinal cancer · 1 Aug 2026 PMID 42541665
- Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD. Breast cancer research and treatment · 8 Jul 2026 PMID 42420599
- A randomized, open-label, two-way crossover clinical trial to evaluate the food effect on pharmacokinetics and safety of DHP107 in patients with advanced solid tumors: the FEEL study. Cancer chemotherapy and pharmacology · 29 May 2026 PMID 42215716
Others — Combination Cancer Therapy (11)
- Inhibitory Effect and Mechanism of Paclitaxel-Loaded Magnetic Iron Oxide Nanomicrobubbles Combined with Ultrasound Therapy on Breast Cancer Xenografts in Nude Mice. Molecular pharmaceutics · 2 Nov 2026 PMID 42969698
- Integrated Spatial Multi-Omics Reveals Metabolic Hotspots of Paclitaxel Biosynthesis in Taxus yunnanensis. Plant communications · 28 Oct 2026 PMID 42947487
- IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA. Medical oncology (Northwood, London, England) · 10 Sept 2026 PMID 42720822
- Melittin-modified Paclitaxel Liposomes as a Synergistic Strategy for Anti-keloid Therapy. The AAPS journal · 9 Sept 2026 PMID 42711616
- Injectable and sprayable supramolecular prodrug hydrogel for long-acting chemo-hormonal therapy of prostate cancer. Journal of controlled release : official journal of the Controlled Release Society · 30 Jul 2026 PMID 42532148
- Fabrication of paclitaxel loaded PLA/PCN-224 metal-organic framework for targeted high-intensity focused ultrasound driven sonodynamic therapy on hypoxia alleviated liver cancer cells. Journal of photochemistry and photobiology. B, Biology · 13 Jul 2026 PMID 42442254
- Synergistic anticancer potential of andrographolide and paclitaxel: a dose-reduction strategy to minimize toxicity and enhance therapeutic efficacy. Drug development and industrial pharmacy · 26 Jun 2026 PMID 42359982
- A tracheal stent integrating sustained release of paclitaxel/resiquimod and hyperthermia potentiates systemic antitumor immunity for enhanced malignant tracheal stenosis treatment. Journal of controlled release : official journal of the Controlled Release Society · 18 Jun 2026 PMID 42314990
- Fluorinated Chitosan-Based Theranostic Nanocarrier System for Image-Guided Synergistic Treatment of Hepatocellular Carcinoma. Molecular pharmaceutics · 8 Jun 2026 PMID 42252614
- Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma. Computers in biology and medicine · 3 Jun 2026 PMID 42235267
- Targeting Cancer Cells With Co(III)-Bipyridyl Complex: A Combined In Vitro and In Silico Study on U87MG and ME-180 Cell Lines. Chemistry & biodiversity · 30 May 2026 PMID 42216859
By study type
Clinical trials (4)
- Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. NEJM evidence · 25 Aug 2026 PMID 42640170
- Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD. Breast cancer research and treatment · 8 Jul 2026 PMID 42420599
- A randomized, open-label, two-way crossover clinical trial to evaluate the food effect on pharmacokinetics and safety of DHP107 in patients with advanced solid tumors: the FEEL study. Cancer chemotherapy and pharmacology · 29 May 2026 PMID 42215716
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189888
Observational studies and case reports (3)
- HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy. BMJ case reports · 24 Aug 2026 PMID 42637511
- Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report. Journal of gastrointestinal cancer · 1 Aug 2026 PMID 42541665
- Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Cesarean Radical Hysterectomy in Pregnant Patients With Cervical Cancer: Obstetric, Neonatal, and Surgical Outcomes. The journal of obstetrics and gynaecology research · 23 Jul 2026 PMID 42489393
Human data, design not indexed (5)
- Development and clinical validation of HPLC method for precise quantification of paclitaxel in plasma from breast cancer patients. PloS one · 8 Oct 2026 PMID 42848832
- Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer. ImmunoHorizons · 22 Sept 2026 PMID 42772938
- Melittin-modified Paclitaxel Liposomes as a Synergistic Strategy for Anti-keloid Therapy. The AAPS journal · 9 Sept 2026 PMID 42711616
- Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia. Journal of medical economics · 31 Jul 2026 PMID 42535775
- Photothermal and photo-oxidation mediated release of lipophilic paclitaxel from liposomes: from formulation to in vitro efficacy and molecular dynamics simulations. International journal of pharmaceutics · 14 Jul 2026 PMID 42447941
Preclinical: animal, cell and lab studies (26)
- Morphology-Tunable Nanoparticles of Aspartic Acid Paclitaxel Conjugates for Breast Cancer Treatment. ACS nano · 10 Nov 2026 PMID 43007796
- Inhibitory Effect and Mechanism of Paclitaxel-Loaded Magnetic Iron Oxide Nanomicrobubbles Combined with Ultrasound Therapy on Breast Cancer Xenografts in Nude Mice. Molecular pharmaceutics · 2 Nov 2026 PMID 42969698
- Anisotropic microgels for spatiotemporal co-delivery of anticancer drugs. Journal of materials chemistry. B · 12 Oct 2026 PMID 42862621
- IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA. Medical oncology (Northwood, London, England) · 10 Sept 2026 PMID 42720822
- Multifunctional nanoparticles for co-delivery of elacridar and paclitaxel for breast cancer local treatment. International journal of pharmaceutics · 31 Aug 2026 PMID 42674320
- Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS. Human cell · 24 Aug 2026 PMID 42635882
- A mitochondria targeting aggregation-induced emission phototheranostic agent for photodynamic synergistic therapy of triple-negative breast cancer. Journal of materials chemistry. B · 19 Aug 2026 PMID 42615305
- Reductive microenvironment-activated paclitaxel-BODIPY nanoassemblies for self-reporting drug delivery. Organic & biomolecular chemistry · 18 Aug 2026 PMID 42610199
- FA receptor-targeted pH-sensitive polymeric micelles co-encapsulating quercetin and paclitaxel for synergistic reversal of drug resistance in non-small cell lung cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology · 17 Aug 2026 PMID 42607382
- Theranostic silica nanoparticles for selective and simultaneous delivery of paclitaxel and coumarin to hypoxic tumors. International journal of pharmaceutics · 16 Aug 2026 PMID 42604719
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment. Biomedical microdevices · 11 Aug 2026 PMID 42579029
- Light-driven reconfiguration of catanionic self-assembly enables bidirectional modulation of drug-release kinetics. Journal of materials chemistry. B · 11 Aug 2026 PMID 42578394
- Self-assembled paclitaxel-loaded spermidine-geranic acid ionic liquid nanoaggregates: preparation, enhanced cellular uptake, and antitumor efficacy. International journal of pharmaceutics · 1 Aug 2026 PMID 42542261
- Injectable and sprayable supramolecular prodrug hydrogel for long-acting chemo-hormonal therapy of prostate cancer. Journal of controlled release : official journal of the Controlled Release Society · 30 Jul 2026 PMID 42532148
- Tumor microenvironment improved by nanostructured lipid carriers co-delivering paclitaxel and ubenimex to treat breast cancer. Drug development and industrial pharmacy · 27 Jul 2026 PMID 42505014
- Nanoagglomerate-enabled inhaled paclitaxel nanoparticle delivery for lung cancer chemotherapy: Proof-of-concept biodistribution and efficacy studies in biorelevant in vitro and in vivo models. International journal of pharmaceutics · 20 Jul 2026 PMID 42476273
- Fabrication of paclitaxel loaded PLA/PCN-224 metal-organic framework for targeted high-intensity focused ultrasound driven sonodynamic therapy on hypoxia alleviated liver cancer cells. Journal of photochemistry and photobiology. B, Biology · 13 Jul 2026 PMID 42442254
- Discovery of highly selective and potent CYP1B1 inhibitors for overcoming paclitaxel resistance in A549/Taxol cells. European journal of medicinal chemistry · 4 Jul 2026 PMID 42401084
- Synergistic anticancer potential of andrographolide and paclitaxel: a dose-reduction strategy to minimize toxicity and enhance therapeutic efficacy. Drug development and industrial pharmacy · 26 Jun 2026 PMID 42359982
- A tracheal stent integrating sustained release of paclitaxel/resiquimod and hyperthermia potentiates systemic antitumor immunity for enhanced malignant tracheal stenosis treatment. Journal of controlled release : official journal of the Controlled Release Society · 18 Jun 2026 PMID 42314990
- Preparation of bovine serum albumin-γ-cyclodextrin conjugate and its solubilization and delivery performance for paclitaxel. Carbohydrate polymers · 12 Jun 2026 PMID 42285666
- Fluorinated Chitosan-Based Theranostic Nanocarrier System for Image-Guided Synergistic Treatment of Hepatocellular Carcinoma. Molecular pharmaceutics · 8 Jun 2026 PMID 42252614
- Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma. Computers in biology and medicine · 3 Jun 2026 PMID 42235267
- Hierarchical polymer-drug nanoplatform with polydopamine shell and folate targeting for synergistic cancer therapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235199
- Targeting Cancer Cells With Co(III)-Bipyridyl Complex: A Combined In Vitro and In Silico Study on U87MG and ME-180 Cell Lines. Chemistry & biodiversity · 30 May 2026 PMID 42216859
Unclassified: not yet indexed with MeSH (3)
- Integrated Spatial Multi-Omics Reveals Metabolic Hotspots of Paclitaxel Biosynthesis in Taxus yunnanensis. Plant communications · 28 Oct 2026 PMID 42947487
- 10-gingerol potentiates paclitaxel efficacy in triple-negative breast cancer by remodeling gut microbiota and suppressing PI3K/AKT/mTOR signaling pathway. Toxicology and applied pharmacology · 7 Oct 2026 PMID 42843603
- Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 20 Jul 2026 PMID 42474029
Written from 41 PubMed abstracts, each one listed by PMID above. Published: 2026-06-13. Last written: 2026-09-24 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.